SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
Pictured: Office building science collage
Career Advice
The Top 12 Companies Hiring in Biopharma Now
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
August 7, 2025
 · 
1 min read
 · 
Chantal Dresner
Close-up image of human hand holding wrench. Construction
Earnings
Biopharma CEOs Can’t Dodge Policy Questions as Trump Lobs Wrench into Earnings Season
From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.
August 6, 2025
 · 
6 min read
 · 
Annalee Armstrong
AbbVie's office in South San Francisco, California
Earnings
AbbVie Pats Own Back as Skyrizi and Rinvoq Rake in Billions
Move over Humira, Skyrizi and Rinvoq are expected to beat the former megablockbuster’s peak sales by the end of this year.
July 31, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
woman hand is removing hair from blue brush. A Hair care.
Immunology and inflammation
AbbVie Carves Out Niche for Rinvoq With ‘Impressive’ Alopecia Areata Data
Rinvoq’s efficacy in alopecia areata is “impressive,” according to Guggenheim analysts, who said the drug could have a competitive edge over other JAK inhibitors in the space.
July 31, 2025
 · 
2 min read
 · 
Tristan Manalac
Raleigh, North Carolina, skyline
Job Trends
7 Companies Hiring in North Carolina
Looking for a biopharma job in North Carolina? Check out the BioSpace list of seven companies hiring life sciences professionals like you.
July 31, 2025
 · 
1 min read
 · 
Angela Gabriel
Aerial view of downtown Los Angeles
Job Trends
11 Companies Hiring in California
Looking for a biopharma job in California? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.
July 23, 2025
 · 
2 min read
 · 
Angela Gabriel
Modern tower buildings in financial district on sunny day in Chicago
Job Trends
6 Companies Hiring in Illinois
Looking for a biopharma job in Illinois? Check out the BioSpace list of six companies hiring life sciences professionals like you.
July 17, 2025
 · 
1 min read
 · 
Angela Gabriel
AbbVie's office in South San Francisco, California
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
The deal, which involves a $700 million upfront payment, gives AbbVie access to ISB 2001, a clinical-stage first-in-class trispecific antibody currently being tested for certain kinds of multiple myeloma as well as autoimmune indications.
July 10, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Podcast
Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More
H2 2025 catalysts to watch, biopharma implications of President Trump’s tax law, KalVista’s new hereditary angioedema drug that Marty Makary reportedly tried to reject, another lawsuit aimed at Health Secretary Robert F. Kennedy Jr. and a plea from patients with ALS for access to BrainStorm’s NurOwn.
July 9, 2025
 · 
1 min read
 · 
Heather McKenzie
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Press Releases
AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
July 31, 2025
 · 
18 min read
Press Releases
AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
July 30, 2025
 · 
12 min read
Press Releases
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
July 11, 2025
 · 
7 min read
Press Releases
AbbVie to Host Second-Quarter 2025 Earnings Conference Call
July 1, 2025
 · 
1 min read
Press Releases
AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
June 30, 2025
 · 
6 min read
Press Releases
Elahere Market Opportunities and Strategies to 2034: Abbvie Secures European Approval for Elahere in Platinum-Resistant Ovarian Cancer
June 25, 2025
 · 
7 min read
Press Releases
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
June 18, 2025
 · 
10 min read
Press Releases
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
June 17, 2025
 · 
10 min read
Press Releases
Genentech Provides Update on Phase III Verona Study
June 16, 2025
 · 
8 min read
Press Releases
U.S. FDA Approves Expanded Indication for AbbVie’s MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
June 11, 2025
 · 
11 min read
Load More